JLL sees roll-up potential for pharma services after $2.6 bln DSM deal
JLL Partners co-founder Paul S. Levy is expecting more acquisitions after the firm closed a carve-out transaction valued at $2.6 billion to combine its Patheon portfolio company with Dutch-based DSM’s pharmaceutical unit, in a deal that drew $200 million in co-investments from the New York firm’s limited partners.
19 November 2013•2 mins read
